【国家卫生健康委讯】近日，国家卫生健康委员会发布消息，我国药品耗材集中带量采购工作取得显著进展。截至目前，国家层面已成功开展了九批共计374个药品和四批医用耗材的集中带量采购。这一系列举措不仅有效提升了药品和耗材的质量和供应保障能力，而且推动了药品价格的合理下降。
据了解，通过国家和省级集采，各省份实现了集采药品数合计超过450种，这意味着广大患者能够以更加优惠的价格获取到质量可靠的药品。这一政策的实施，不仅减轻了患者的经济负担，也促进了医疗资源的合理分配，提高了医疗服务的整体效率。
国家卫生健康委表示，将继续深化药品耗材集中带量采购改革，不断完善相关政策措施，确保药品耗材质量和供应，为人民群众提供更加安全、有效、经济的医疗服务。同时，也将继续推动药品耗材价格合理回归，促进医药行业的健康发展和市场竞争的有序进行。
此次集采工作的提速扩面，是深化医药卫生体制改革的重要举措，对于推动我国医药市场规范化、透明化具有重要意义。未来，随着集采工作的深入实施，预计将有更多的药品和耗材纳入集采范围，进一步惠及广大患者。
英语如下：
Title: Over 450 Types of National Procurement Drugs Benefit the Public
Keywords: Pricing Acceleration, Over 450 Drugs, Four Batch of Medical Devices
Content:
[Message from the National Health Commission] Recently, the National Health Commission released a statement indicating that China’s centralized procurement of drugs and medical supplies has made significant progress. To date, the national level has successfully completed nine batches of 374 drugs and four batches of medical device procurement, totaling 374 drugs and four batches of medical devices. This series of measures not only effectively improves the quality and supply guarantee capabilities of drugs and medical devices but also promotes a reasonable decrease in drug prices.
It is understood that through national and provincial procurement, all provinces have achieved a total of over 450 types of procurement drugs, which means that the vast number of patients can obtain reliable quality drugs at more favorable prices. The implementation of this policy not only alleviates the economic burden on patients but also promotes the rational allocation of medical resources and improves the overall efficiency of medical services.
The National Health Commission stated that it will continue to deepen the reform of centralized procurement of drugs and medical devices, improve relevant policies and measures, ensure the quality and supply of drugs and medical devices, and provide safer, more effective, and economical medical services for the people. At the same time, it will also continue to push for the reasonable return of drug and medical device prices, promoting the healthy development of the pharmaceutical industry and the orderly competition in the market.
The acceleration and expansion of the procurement work is an important measure to deepen the reform of China’s medical and health system, and it is of great significance for promoting the standardization and transparency of China’s pharmaceutical market. In the future, as the procurement work is implemented in depth, it is expected that more drugs and medical devices will be included in the procurement scope, further benefiting the vast number of patients.
【来源】http://www.chinanews.com/gn/2024/05-24/10222310.shtml
Views: 6